Viking phase 2b study of NASH candidate hits primary endpoint
VK2809 found that those on the medicine saw statistically significant reductions in liver fat, meeting the primary endpoint.
Investing10m
After-hours movers: Dolby Laboratories, Powell Industries, Keysight Technologies
Revenues totaled $275 million, an increase of 32%, but below the average analyst estimate. Viking Therapeutics (NASDAQ:VKTX) rose 1.7% after it announced that final results from the company's Phase 2b ...